Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine effect on PF-07321332/ritonavir PK
NCT04962230Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration of PF-07321332 at Day 14 and Area Under the Curve From Time Zero to Extrapolated Infinite Time of PF-07321332 at Day 14. Started Jul 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04962230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962230.